Electrophysiological safety of sibutramine HCl

Human and Experimental Toxicology

Volumn 27, Issue 7, 2008, Pages 553-558

  Kim, K S ^a   Park, S J ^a   Lee, H A ^a   Kim, D K ^b   Kim, E J ^a,c  

^a Korea Institute of Toxicology   (South Korea)

^b Konyang University College of Medicine   (South Korea)

^c Korea Research Institute of Chemical Technology   (South Korea)

Author keywords

Action potential; hERG channel; L type Ca channel; Na channel; Sibutramine HCl

Indexed keywords

CALCIUM CHANNEL L TYPE; POTASSIUM CHANNEL HERG; SIBUTRAMINE; SODIUM CHANNEL; AGENTS AFFECTING WATER, MOLECULE OR ION TRANSPORT; ANOREXIGENIC AGENT; CYCLOBUTANE DERIVATIVE;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CALCIUM CURRENT; CARDIOTOXICITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG SAFETY; ELECTROPHYSIOLOGY; EXPERIMENTAL GUINEA PIG; HEART MUSCLE CELL; HEART PAPILLARY MUSCLE; HEART VENTRICLE WALL; IC 50; MALE; MEMBRANE STEADY POTENTIAL; MUSCLE ACTION POTENTIAL; NONHUMAN; POTASSIUM CURRENT; PRIORITY JOURNAL; RAT; SODIUM CURRENT; ACTION POTENTIAL; ANIMAL; DOSE RESPONSE; DRUG EFFECT; GUINEA PIG; HEART VENTRICLE; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY;

CAVIA; RATTUS;

ACTION POTENTIALS; ANIMALS; APPETITE DEPRESSANTS; CYCLOBUTANES; DOSE-RESPONSE RELATIONSHIP, DRUG; ETHER-A-GO-GO POTASSIUM CHANNELS; GUINEA PIGS; HEART VENTRICLES; MALE; MEMBRANE TRANSPORT MODULATORS; MYOCYTES, CARDIAC; PAPILLARY MUSCLES;

EID: 56049102367     PISSN: 09603271     EISSN: None     Source Type: Journal    
DOI: 10.1177/0960327108095991     Document Type: Article

References (7)

1. Nisoli E Carruba MO. An assessment of the safety and efficacy of sibutramine, an anti-obesity drug with a novel mechanism of action. Obes Rev 2000 ; 1: 127 - 139.
2. Kim EJ Park EK Suh KH. Safety pharmacology of sibutramine mesylate, an anti-obesity drug. Hum Exp Toxicol 2005 ; 24: 109 - 119.
3. Luque CA Rey JA. Sibutramine: a serotonin-norepinephrine reuptake-inhibitor for the treatment of obesity. Ann Pharmacother 1999 ; 33: 968 - 978.
4. Zannad F Gille B Grentzinger A Bruntz JF Hammadi M Boivin JM. Effects of sibutramine on ventricular dimensions and heart valves in obese patients during weight reduction. Am Heart J 2002 ; 144: 508 - 515.
5. Buckett WR Thomas PC Luscombe GP. The pharmacology of sibutramine hydrochloride (BTS 54 524), a new antidepressant which induces rapid noradrenergic down-regulation. Prog Neuropsychopharmacol Biol Psychiatry 1988 ; 12: 575 - 584.
6. Abolfathi Z Couture J Vallee F LeBel M Tanguay M Masson E. A pilot study to evaluate the pharmacokinetics of sibutramine in healthy subjects under fasting and fed conditions. J Pharm Pharm Sci 2004 ; 127: 345 - 349.
7. Redfern WS Carlsson L Davis AS Lynch WG MacKenzie I Palethorpe S. Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development. Cardiovasc Res 2003 ; 58: 32 - 45.